Pharmacogenomics Market 2017

Report ID : RNR-199990 Category : Pharma Healthcare Published Date : Dec-17
Publisher : Research-N-Reports Pages : 123 Format : PDF
Research N Reports added new report titled, “Pharmacogenomics (PGx) Market by Technology (Polymerase Chain Reaction (PCR), Microarray, Sequencing); by Ecosystem Players (Diagnostic Test, Pharmaceutical, Others); by Therapeutic Application (Oncology, Cardiovascular, Others); by Regions (North America, Asia Pacific, Europe, the Middle East & Africa and Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2017-2025.”

The Global Pharmacogenomics (PGx) Market growth is progressively gaining speed as a huge number of government initiatives and research & development programs have been introduced in the last few years. Development and invention of new healthcare technologies such as next-generation sequencing, High Throughput Screening (HTS), and Digital PCR are mounting the platform for growth. The Market, which was esteemed at US$ XX billion in 2017, is relied upon to achieve an estimation of US$ XX billion by 2025, developing at a CAGR of XX% amid the forecast time frame 2017-2025. The US market alone is forecast to be worth $XX billion in 2025, accounting for XX% of the overall Pharmacogenomics (PGx) market. 

On the basis of technology, the market is segmented into Polymerase Chain Reaction (PCR), microarray, sequencing and other technologies. Sequencing segment is further segmented into pyrosequencing, Sanger sequencing, and Next-Generation Sequencing (NGS). Other technologies are further segmented into mass spectrometry and electrophoresis.

Observing current patterns, Big Data organizations are incorporating into service provider segments and are teaming up and entering into partnerships with healthcare suppliers, pharmaceuticals & biotechnology organizations, and academic institutions to help the development of the PGx market. As a consequence, the service segment is estimated to develop at a high CAGR of XX% from 2017 to 2025. Additionally, the Pharmaceutical segment will likewise gain from traction in number of patients because of expanding mindfulness about the advantages of PGx solutions and adoption of these solutions in developing regions.

The market growth is propelled due to factors such as: 
• Rising usage in drug discovery processes.
• Increasing demand for pharmacogenomics & precise drugs.
• Technological innovation and advancement.
• Increasing genetic disorder/abnormalities.
• Government support and regulations.
Government regulations and standards are supporting the development and advancement of the PGx market. The fundamental objective of these standards is to make the PGx solutions more versatile and centered toward oncology, pain management, the central nervous system (CNS), Cardiovascular (CVD), and infectious diseases among others.

In North America, existing players are incorporating with new companies through partnerships and cooperation to capture the regional segment. The regions local players are entering in other emerging nations to capture more pieces of the overall industry. All through the Asia-Pacific and European nations, administrative bodies are rolling out standards to keep a check of most recent advancements. North America is the largest contributor to the revenue generation in PGx market followed by Europe and is expected to grow at a high CAGR of XX% from 2017 to 2025. APAC is expected to show the fastest growth globally and is expected to grow at XX% CAGR over the research period. The region is concentrating more on innovative development and presentation of new gene sequencing and gene mapping instruments into medicinal services frameworks to develop particular laboratory diagnostic tests.

The report provides both, qualitative and quantitative research of the Global Pharmacogenomics (PGx) Market, as well as encompasses worthy insights into the rational scenario and favored improvement methods adopted by key contenders. Some of the primary players of Global Pharmacogenomics (PGx) Market are Abbott Laboratories, Affymetrix, Inc., Assurex Health, Inc., Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Pathway Genomics, Pfizer, Inc., Qiagen, Inc., Roche Holding Ag-Br, and Teva Pharmaceutical Industries Ltd., among others.
1 Report Overview 
1.1 Report Scope 
1.1.1 Report Coverage 
1.1.2 Assumptions And Limitations 
1.1.3 Market Classification & Segmentation 
1.2 Research Methodology 
1.2.1 Data Points Considered For Market Size Estimation 
1.2.2 Key Data Point Sources Key Data Points From Primary Sources Key Data Points From Secondary Sources 
1.2.3 Data Triangulation 
1.2.4 Top-Down Approach 
1.2.5 Bottom-Up Approach 
1.3 Report Description 
2 Executive Summary 
2.1 Global Market Scenario 
3 Market Overview 
3.1 Introduction 
3.2 Pharmacogenomics: Mechanism Of Action 
3.3 Role Of Companion Diagnostics In PGX 
3.4 Role Of Biomarkers In PGX 
3.5 Role Of Molecular Diagnostics In PGX 
3.6 Benefits Of PGX 
3.7 End-Use Applications Of PGX 
3.8 Market Dynamics 
3.8.1 Market Drivers 
3.8.2 Market Challenges 
3.8.3 Market Opportunities 4 Competitive Insights 
4.1 Key Market Developments & Strategies 
4.1.1 Competitive Landscape Of Some Of The Key Players 
4.1.2 Partnerships, Joint Ventures And Collaborations Key Insights Recent Partnerships, Joint Ventures And Collaborations 
4.1.3 Product Launch And Developments Key Insights Recent Product Launch And Developments 
4.1.4 Patents, Licensing, Certification And Approvals Key Insights Recent Patents, Licensing, Certification And Approvals 
4.1.5 Mergers And Acquisitions Key Insights Recent Mergers And Acquisitions 
4.1.6 Business Contracts And Business Expansions Key Insights Recent Business Contracts And Business Expansions 
4.1.7 Other Strategies Key Insights Recent Developments Of Other Strategies 
4.2 Porter’s Five Forces Analysis 
4.2.1 Threat Of Substitutes 
4.2.2 Threat Of New Entrants 
4.2.3 Bargaining Power Of Buyers 
4.2.4 Bargaining Power Of Suppliers 
4.2.5 Intensity Of Competitive Rivalry 5 Industry Analysis 
5.1 Patent Analysis 
5.1.1 Some Of The Key Players 
5.1.2 Others (University/Hospital/Person) 
5.2 Regulations, Consortiums, Certifications, & Standards 
5.2.1 Regulatory Bodies 
5.2.2 Examples Of Some Common Acts Certifications 
5.3 Value Chain Analysis 
6 Global Pharmacogenomics Market By Technology 
6.1 Market Segmentation By Technology 
6.2 Microarray 
6.2.1 Introduction 
6.2.2 Microarray: Types, Applications & Key Players 
6.2.3 Microarray: Market Dynamics & Recent Developments 
6.3 Sequencing 
6.3.1 Introduction 
6.3.2 Sequencing: Market Dynamics, Applications & Key Players 
6.3.3 Types Of Sequencing Technologies Sanger Sequencing Pyrosequencing Next-Gen Sequencing (NGS) Next-Gen Sequencing (NGS) Applications & Key Players Next-Gen Sequencing (NGS) Recent Developments 
6.4 Polymerase Chain Reaction (PCR) 
6.4.1 Introduction 
6.4.2 PCR Types 
6.4.3 PCR: Market Dynamics, Applications & Key Players 
6.5 Other Technologies 
6.5.1 Mass Spectrometry 
6.5.2 Electrophoresis 
7 Global Pharmacogenomics Market By Ecosystem Players 
7.1 PGX Ecosystem Players: Overview 
7.2 Market Segmentation By Ecosystem Players 
7.2.1 Market Insights & Statistics 
7.3 Diagnostic Test Companies 
7.3.1 Introduction 
7.3.2 Market Statistics 
7.3.3 Diagnostic Companies: Drivers & Challenges 
7.3.4 Recent Key Developments 
7.3.5 Key Players 
7.4 Pharmaceuticals Companies 
7.4.1 Introduction 
7.4.2 Market Statistics 
7.4.3 Drug Development Process 
7.4.4 Role Of Pharmaceutical Companies & Example Of Some Drugs 
7.4.5 Pharmaceuticals Companies: Drivers & Challenges 
7.4.6 Recent Key Developments 
7.4.7 Key Players 
7.5 Service Providers 
7.5.1 Introduction 
7.5.2 Market Statistics 
7.5.3 Service Provider: Roles & Big Data Benefits 
7.5.4 Big Data Companies: Drivers & Challenges 
7.5.5 Recent Key Developments 
7.5.6 Key Players 
8 Global Pharmacogenomics Market By Therapeutic Applications 
8.1 Market Segmentation 
8.2 Market Statistics 
8.3 Cancer/Oncology 
8.3.1 Key Insights & Statistics 
8.3.2 Market Statistics 
8.3.3 Types Of Cancer 
8.3.4 Cancer: Examples Of Some Drugs 
8.3.5 Cancer: Examples Of Some Tests 
8.3.6 Market Dynamics & Key Players 
8.3.7 Recent Key Developments 
8.4 Cardiovascular Diseases (CVD) 
8.4.1 Key Insights & Statistics 
8.4.2 Market Statistics 
8.4.3 CVD: Examples Of Some Drugs 
8.4.4 CVD: Examples Of Some Tests 
8.4.5 Recent Key Developments & Key Players 
8.5 Central Nervous System(CNS) 
8.5.1 Key Insights & Statistics 
8.5.2 Market Statistics 
8.5.3 CNS: Examples Of Some Drugs 
8.5.4 CNS: Examples Of Some Tests 
8.5.5 Recent Key Developments & Key Players 
8.6 Infectious Diseases 
8.6.1 Key Insights & Statistics 
8.6.2 Market Statistics 
8.6.3 Infectious Diseases : Examples Of Some Drugs 
8.6.4 Recent Key Developments & Key Players 
8.7 Other Diseases 
8.7.1 Key Insights & Statistics 
8.7.2 Market Statistics 
8.7.3 Other Diseases : Examples Of Some Drugs 
8.7.4 Other Diseases : Examples Of Some Tests 
8.7.5 Recent Key Developments & Key Players 
9 Global Pharmacogenomics Market By Geography 
9.1 Geographical Scenario 
9.2 Market Insights & Statistics 
9.3 North America 
9.3.1 Market Scope 
9.3.2 North America: Market Insights & Statistics 
9.3.3 North American Market Dynamics 
9.3.4 Key Regulatory Bodies & Associations 
9.3.5 The U.S. The U.S.: Market Statistics The U.S.: Key Insights 
9.3.6 Canada 
9.3.7 Recent Key Developments 
9.4 Europe 
9.4.1 Market Scope 
9.4.2 Europe: Market Insights & Statistics 
9.4.3 European Market Dynamics 
9.4.4 Key Regulatory Bodies & Associations 
9.4.5 The U.K. 
9.4.6 Germany 
9.4.7 Recent Key Developments 
9.5 Asia-Pacific (APAC) 
9.5.1 Market Scope 
9.5.2 APAC: Market Insights & Statistics 
9.5.3 APAC Market Dynamics 
9.5.4 China 
9.5.5 Japan 
9.5.6 India 
9.5.7 Recent Key Developments 
9.6 Rest Of The World (ROW) 
9.6.1 ROW: Market Insights & Statistics 
9.6.2 Middle East 
9.6.3 South America 
9.6.4 Africa 
9.6.5 Recent Key Development 
10 Company Overview 
10.1 Abbott Laboratories 10.1.1 Overview 
10.1.2 Financials 
10.1.3 Financial Summary 10.1.4 Key Developments 10.1.5 SWOT Analysis 
10.2 Affymetrix, Inc. 10.2.1 Overview 10.2.2 Financials 
10.2.3 Financial Summary 10.2.4 Key Developments 10.2.5 SWOT Analysis 
10.3 Assurex Health, Inc. 10.3.1 Overview 
10.3.2 Key Developments 10.3.3 SWOT Analysis 
10.4 Astrazeneca 
10.4.1 Overview 
10.4.2 Financials 
10.4.3 Financial Summary 
10.4.4 Key Developments 
10.4.5 SWOT Analysis 
10.5 Illumina, Inc. 10.5.1 Overview 10.5.2 Financials 
10.5.3 Financial Summary 10.5.4 Key Developments 10.5.5 SWOT Analysis 
10.6 Laboratory Corporation Of America Holdings 10.6.1 Overview 
10.6.2 Financials & Financial Summary 10.6.3 Key Developments 
10.6.4 SWOT Analysis 
10.7 Myriad Genetics, Inc. 
10.7.1 Overview 
10.7.2 Financials & Financial Summary 
10.7.3 Key Developments 
10.7.4 SWOT Analysis 
10.8 Pfizer, Inc. 
10.8.1 Overview 
10.8.2 Financials 
10.8.3 Financial Summary 
10.8.4 Key Developments 
10.8.5 SWOT Analysis 
10.9 Qiagen, Inc. 10.9.1 Overview 10.9.2 Financials 
10.9.3 Financial Summary 10.9.4 Key Developments 10.9.5 SWOT Analysis 
10.10 Roche Holding AG-BR 10.10.1 Overview 
10.10.2 Financials 
10.10.3 Financial Summary 10.10.4 Key Developments 10.10.5 SWOT Analysis 
10.11 TEVA Pharmaceutical Industries Ltd. 10.11.1 Overview 
10.11.2 Financials 
10.11.3 Financial Summary 10.11.4 Key Developments 10.11.5 SWOT Analysis 
10.12 Thermo Fisher Scientific 
10.12.1 Overview 
10.12.2 Financials 
10.12.3 Financial Summary 
10.12.4 Key Developments 
10.12.5 SWOT Analysis 
10.13 Transgenomic, Inc. 10.13.1 Overview 
10.13.2 Financials & Financial Summary 10.13.3 Key Developments 
10.13.4 SWOT Analysis 
10.14 Other Emerging Companies 10.14.1 Diagnostic Test Companies Companiondx Reference Lab, LLC Mapmy Genome Asuragen 23andme Cnsdose 
10.14.2 Pharmaceutical Companies Actinium Pharmaceuticals, Inc Foundation Medicine 
10.14.3 Service Providers PGX Software LLC Gene Logic Genewiz Conatus Consulting, LLC 10.14.4 Care Providers Gene DX Mayo Clinic